Genetically altered microbes are used widely in the conduct of scientific study and have facilitated the development of new medical therapies, preventive strategies, and diagnostic tools. Unfortunately, such organisms may also cause infectious disease outbreaks as a result of accidental or intentional transmission to humans. The unique microbial properties of genetically altered pathogens and the clinical symptoms exhibited by persons infected with them may impede the usual diagnostic and clinical evaluations or preventive strategies. Practicing physicians and clinicians at microbiology laboratories, who would be the first to observe such infections, must consider the broad clinical possibilities of illnesses caused by deliberately altered microorganisms and the potential difficulty in confirming a diagnosis.
Recent advances in biotechnology have resulted in the widespread use of genetically altered microbes to develop new medical therapies, preventive strategies, and diagnostic tools-for example, they may be used in techniques to create vaccines, purify proteins, construct cloning vectors, study pathogenesis, and understand complex interactions of immune and biologic responses. Although genetic modification of microbes has been productively employed in legitimate scientific pursuits, the same tools for modification may also be used to develop microbes with characteristics that increase their threat as infectious agents, such as enhanced resistance to antibiotics, heightened pathogenicity, increased ability to evade vaccine-induced adaptive immunity, failure to be detected by standard clinical and laboratory diagnostic tools, and altered transmission properties. Thus, as security experts have recognized for some time, biotechnology has a "dual use" capability: it may be applied in many beneficial ways or it may be employed to develop microbes capable of great harm [1, 2] .
BIOENGINEERED AGENTS AS MICROBIAL WEAPONS
Current assessments of the threat that bioengineered microbes may be used by terrorists have been informed by revelations of the huge biological weapons program of the former Soviet Union, known as "Biopreparat," which employed 125,000 Soviet scientists at 18 or more facilities for research, development, production, and mobilization [3] . According to Dr. Vladimir Pasechnik [3] , who defected from the former Soviet Union in 1989, microbiologists at the State Research Center for Applied Microbiology in Obolensk, a premier Biopreparat facility, developed in 1983 their first genetically altered microbe for use as a weapon-a hypervirulent strain of Francisella tularensis, the causative agent of tularemia. Dr. Ken Alibek, formerly the First Deputy Director of Biopreparat, who defected to the United States in 1991, has described research efforts by Soviet scientists to insert the genes of Venezuelan equine encephalitis virus, b-endorphin, and Ebola virus into variola (the virus that causes smallpox) and to develop antigenically altered Bacillus anthracis (the causative agent of anthrax) strains that can resist anthrax vaccines and antibiotics [4] .
More recently, Dr. Sergei Popov, who had worked at both the State Research Center of Virology and Biotechnology (also known as "Vector") (Koltsovo, Novosibsk region) and at the Obolensk facility, described Biopreparat's Project Bonfire, whose goal was to develop antibiotic-resistant microbial strains, and Project Factor, whose goal was to create microbial weapons Ebola vp24 gene [10] b-endorphin gene [11] Tickborne encephalitis virus protein E gene [12] Venezuelan equine encephalitis 26S RNA [13] Marburg virus nucleoprotein gene [14] Tickborne encephalitis virus structural and nonstructural proteins genes [15, 16] Myelin basic protein gene [17] with new biologic properties that would result in high virulence, improved stability, and new clinical syndromes [5] . In addition, many thousands of recombinant microbes are generated every year worldwide as a result of legitimate microbiological investigations. Antibiotic-resistance genes are commonly inserted into bacteria as a means to select for the recombinant genes under study. Recombinant techniques, including those developed for the insertion of viral genes into vaccinia, have been used extensively in the development of new bacterial and viral vaccines [49, 50] . These microbes, as well as many other genetically altered microorganisms, present a potential threat if they become the source of an unnatural-either accidental or intentional-infectious disease outbreak [51] .
RECOGNITION OF OUTBREAKS CAUSED BY EMERGING MICROBES
The diagnosis of illnesses caused by conventional pathogens rests on the recognition of symptoms by physicians, with the subsequent use of appropriate laboratory tests to confirm or refute the suspected diagnoses. Recent outbreaks of emerging infectious diseases underscore the critical importance of observant and knowledgeable medical practitioners for recognizing new infections. The first descriptions of HIV and AIDS came from Los Angeles physicians who cared for homosexual men with Pneumocystis jiroveci (formerly known as Pneumocystis carinii) pneumonia and T cell immunodeficiency [52, 53] . The first recognition of human West Nile virus infection in the United States resulted from a report to the New York City Department of Health of 2 unusual cases of encephalitis by an infectious diseases physician in northern Queens [54] . The initial case in the anthrax outbreak associated with contaminated mail was diagnosed by an infectious diseases physician in Florida [55] . Finally, the first cases of monkeypox during the recent outbreak associated with infected prairie dogs were recognized by physicians in Wisconsin [56] . Thus, practicing physicians and clinical microbiology laboratories have, in the recent past, played key roles in identifying sentinel patients among previously unrecognized disease clusters caused by either natural or unnatural infectious diseases, and there is every reason to believe that similar scenarios will occur in the future. Table 4 summarizes characteristics that may suggest a genetically modified microbe as the infectious agent.
ALTERED EPIDEMIOLOGIC PICTURE
The epidemiologic characteristics of outbreaks caused by genetically modified agents-either intentionally bioengineered or naturally modified-may be altered from typical characteristics in many possible ways. For example, bioengineered microbes may cause infections with an unexpected geographic distribution, such as cases occurring in regions where the disease is not known to be endemic or epidemic; unexpected NOTE. rTNF, recombinant tumor necrosis factor; VEE, Venezuelan equine encephalomyelitis virus.
a Genes used to create hybrid proteins. [Leu5]enkephalin gene E. coli [48] transmission characteristics, such as person-to-person transmission of an illness that resembles anthrax; an unexpected age distribution of cases, such as a childhood illness appearing in adults who were considered to be immune; or unexpectedly high mortality rates. Furthermore, infections due to genetically altered microbes may cluster among ethnic or occupational groups or among individuals with a common travel history. Of particular concern are outbreaks of human infections caused by zoonotic disease agents, which may occur concomitantly with animal illnesses and deaths. Thus, infectious disease outbreaks caused by genetically altered microbes may exhibit unexpected or unusual epidemiologic features. Questions or concerns about such outbreaks or case clusters on the part of practicing physicians should be directed to local or state public health officials.
ALTERED CLINICAL PICTURE
Although diseases such as plague, anthrax, tularemia, viral hemorrhagic fevers, pox virus infections, and botulism are rare in the United States, patients presenting with these illnesses usually display classic symptoms that suggest a specific diagnosis. Illnesses caused by bioengineered microbes, on the other hand, may be characterized by signs and symptoms that are not usually associated with a single agent, such as signs and symptoms that are unusual given the causative agent that was isolated by culture or detected by other diagnostic tests; an unexpected clinical course of the infection; a cluster of symptoms that do not fit the expected clinical picture; or an unexpectedly poor response to standard treatment. Theoretical examples are the appearance of a vesicular rash several days after the onset of severe gastroenteritis, a hemorrhagic rash associated with an infection confirmed to be caused by Venezuelan equine encephalitis virus, or a failure of pneumonic plague to respond to streptomycin or gentamicin therapy. The unusual nature of the clinical picture may result in significant delays in diagnosis even when experienced infectious diseases physicians and public health officials are involved.
Because of the myriad possibilities of genetic alterations that can be made-and have been made-in a large number of bacteria and viruses, a detailed description of the clinical (and epidemiologic) characteristics of infections that may be caused by specific bioengineered microbes is impossible. Rather, the possibility of a genetically altered infecting organism needs to be considered in the assessment of all infectious disease outbreaks, and an appropriate comprehensive diagnostic work-up, in consultation with a reference laboratory and an infectious diseases physician, needs to be employed if it is a plausible consideration. Questions or concerns on the part of practicing 
FAILURE OF DETECTION BY CURRENT DIAGNOSTIC TESTS
Laboratory identification of human bacterial or viral pathogens generally depends on detection of microbial growth on standard media or cell lines, detection of microbial antigens or nucleic acids, or demonstration of a specific serum antibody response. These diagnostic approaches, however, may prove inadequate for identification and characterization of genetically altered microbes (see table 5 ). Antigen-antibody-based diagnostic tests-such as immunohistochemical analysis, direct immunofluorescence assays, antigen-capture ELISA, or bacterial agglutination assay for detection of microbial antigen and ELISA-based assays, complementation fixation assays, passive hemagglutination assays, indirect immunofluorescence assays, a hemagglutination inhibition assay, or a plaque reduction neutralization test for detection of antibody responses-may give false-negative results if the pathogen has been genetically altered to express antigens that do not bind the specific antibodies used in the detection assays or to stimulate antibodies that do not bind standard detection targets.
Biochemistry-based tests used to identify the genus and species of bacteria recovered from clinical specimens depend on the expression of bacterial enzymes or other cell products. Similarly, functional assays, such as hemadsorption, which are important for identification of the presence of viruses in cell culture, depend on the presence of specific viral-encoded proteins.
The genes encoding these products may be genetically altered either intentionally or as an inadvertent result of a genetic manipulation directed at another microbial target, so that the products are not expressed at all or are altered in their structure or function.
Nucleic acid-based diagnostic tests that are used to detect specific gene regions of bacteria or viruses depend on reagents that hybridize to specific nucleotides. Thus, standard primers used in amplification assays may not hybridize to specific gene regions that have been genetically altered. In addition, the digestion products of assays based on restriction fragment-length polymorphisms may not be of the expected size because of genetic alteration in the restriction sites or may not hybridize to organism-specific probes if the gene regions that are expected to hybridize to the probes have been manipulated. Thus, genetically altered microbes may escape detection by standard laboratory diagnostic techniques, and their detection may require the development of new or additional diagnostic reagents or techniques. [59, 60] . Thus, the appearance of infection with a vaccine-preventable threat agent in a previously immunized patient or population suggests the possibility of genetic modification of the causative microbe.
FAILURE OF PROTECTION BY CURRENT VACCINES

SUMMARY
Genetic modifications in bacteria and viruses occur naturally in the course of microbial evolution and, furthermore, are commonly made in the conduct of legitimate scientific experimentation. The intentional or unintentional release of genetically modified organisms into the environment may cause outbreaks of infectious diseases with unusual epidemiological or clinical manifestations. The recognition that certain unusual cases are clustered and represent an outbreak requires a high level of suspicion and broad communication among medical, clinical laboratory, and public health professionals. Electronic information dispersal systems and online bulletin boards (such as ProMED [http://www.promedmail.org]), play an important role in promoting rapid communication. In the assessment of such outbreaks in the future-particularly if they exhibit unusual characteristics-physicians, clinical microbiology laboratories, and public health officials need to consider the possibility of genetically altered microbes as the causative agents.
